Carisma Therapeutics (NASDAQ:CARM) and Hypermarcas (OTCMKTS:HYPMY) Head-To-Head Review

Hypermarcas (OTCMKTS:HYPMY) and Carisma Therapeutics (NASDAQ:CARM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Volatility and Risk

Hypermarcas has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Institutional & Insider Ownership

44.3% of Carisma Therapeutics shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Hypermarcas and Carisma Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hypermarcas	12.51%	6.95%	3.34%
Carisma Therapeutics	-254.28%	-957.20%	-137.38%

Analyst Ratings

This is a summary of recent ratings and target prices for Hypermarcas and Carisma Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hypermarcas	0	0	0	0	0.00
Carisma Therapeutics	0	5	1	1	2.43

Carisma Therapeutics has a consensus target price of $1.93, indicating a potential upside of 336.41%. Given Carisma Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Hypermarcas.

Earnings & Valuation

This table compares Hypermarcas and Carisma Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hypermarcas	$1.38 billion	2.23	$248.62 million	$0.24	20.23
Carisma Therapeutics	$19.63 million	0.94	-$60.48 million	($1.56)	-0.28

Hypermarcas has higher revenue and earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Hypermarcas, indicating that it is currently the more affordable of the two stocks.

Summary

Hypermarcas beats Carisma Therapeutics on 8 of the 15 factors compared between the two stocks.

About Hypermarcas

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.